Opportunity Information: Apply for RFA CA 27 006
The National Cancer Institute (NCI) is soliciting applications for NCORP Research Bases under Funding Opportunity Number RFA-CA-27-006. This opportunity uses the UG1 cooperative agreement mechanism, meaning awardees will carry out the work in close collaboration with NCI staff and within NCI program expectations, rather than operating as fully independent investigator-initiated projects. The overall NCORP program is built to make cancer research findings more generalizable and easier to disseminate by enrolling participants in a wide range of real-world community settings. In practical terms, NCORP aims to bring rigorous clinical trials and other human subjects studies closer to where many patients receive care, while also improving how prevention, screening, cancer control, and care delivery evidence is generated and implemented.
This specific NOFO covers only the NCORP Research Bases component, which is described as the research hub of the NCORP network. Research Bases are expected to design, develop, and run multi-institutional cancer control, prevention, and care delivery (CCP and CD) studies, including quality-of-life studies that can be embedded within treatment or imaging trials. A major emphasis is that these are clinical trial activities (the announcement notes "Clinical Trial Required"), and the Research Base is responsible for the scientific backbone of those efforts, including study concept development, protocol design, statistical leadership, and analysis plans that can support research across multiple participating sites.
Operationally, Research Bases are expected to assume responsibility for the full set of study operations and data management functions needed to run complex, multi-site human subject research. That includes efficient protocol development processes, regulatory compliance, and participant protection requirements aligned with federal expectations and oversight bodies such as the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP). The NOFO also highlights expectations around auditing, training, quality assurance, and providing ongoing support to the community-facing parts of the network (Community Sites and Academic Community Sites). In other words, the Research Base is not just writing protocols; it is expected to maintain the infrastructure and operational discipline that allow many geographically distributed sites to participate consistently, safely, and in compliance with applicable regulations.
NCORP as a whole is structured across three related funding opportunities, and this one should be understood in that broader architecture. Alongside Research Bases, there are separate NOFOs for NCORP Community Sites and NCORP Academic Community Sites; those other components are explicitly described as "Clinical Trials Not Allowed" under the UG1 mechanism, while Research Bases are the component where the clinical trial leadership and requirements sit. NCORP is also positioned to enhance patient and provider access to treatment and imaging trials that are conducted under the National Clinical Trials Network (NCTN), which is NCI's broader national trial system. This means Research Bases may operate in an ecosystem where cancer control and care delivery studies intersect with, or are embedded within, treatment and imaging trials being run through NCTN structures.
The NOFO indicates that Research Bases should be located at institutions with substantial cancer clinical research expertise and established capabilities. Examples listed include NCI-designated Cancer Centers, healthcare research organizations, NCTN Group Operations Centers, or cancer foundations associated with an NCTN Group. The intent is to ensure the awardee has the depth of scientific leadership, biostatistical and data management capacity, regulatory infrastructure, and operational experience to function as a hub coordinating many external sites and managing high-quality multi-institutional research.
Eligibility is broad across many U.S.-based organization types, including various levels of government, public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, tribal governments and tribal organizations, and certain housing authorities. However, there are clear restrictions on foreign participation: non-U.S. (non-domestic) organizations are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. At the same time, "foreign components" as defined in the NIH Grants Policy Statement are allowed, which typically means discrete parts of the project may involve foreign collaboration under NIH rules, but the applicant organization and eligible components must remain domestic per the NOFO.
Administratively, the sponsoring agency is the National Institutes of Health (NIH), with NCI as the lead institute, and the activity category is Health. The CFDA (Assistance Listing) numbers are 93.393 and 93.399. The opportunity is discretionary, the funding instrument is a cooperative agreement, and the anticipated number of awards is 7. The original closing date listed is 2026-09-18. No award ceiling is specified in the provided source text.Apply for RFA CA 27 006
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
- This funding opportunity was created on 2026-05-21.
- Applicants must submit their applications by 2026-09-18. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 7 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a National Cancer Institute (NCI) funding opportunity to support NCORP Research Bases under Funding Opportunity Number (FON) RFA-CA-27-006. It is part of the NCI Community Oncology Research Program (NCORP) and focuses specifically on the Research Base component of the overall NCORP network.
Which agency is offering this opportunity?
The sponsoring agency is the National Institutes of Health (NIH), with the National Cancer Institute (NCI) serving as the lead institute.
What is the funding mechanism for this NOFO?
The award uses the UG1 cooperative agreement mechanism. This means funded applicants will carry out the work in close collaboration with NCI staff and within NCI program expectations, rather than operating as fully independent investigator-initiated projects.
Is this opportunity considered a clinical trials program?
Yes. The announcement indicates "Clinical Trial Required" for this Research Base NOFO, reflecting that clinical trial activities and leadership are a core expectation of the Research Base role.
What part of NCORP does this NOFO cover?
This NOFO covers only the NCORP Research Bases component, described as the research hub of the NCORP network. Separate NOFOs exist for NCORP Community Sites and NCORP Academic Community Sites.
How do Research Bases differ from Community Sites and Academic Community Sites?
Research Bases are where the clinical trial leadership and requirements sit. In contrast, the separate NOFOs for Community Sites and Academic Community Sites are described as "Clinical Trials Not Allowed" under the UG1 mechanism.
What is the overall purpose of NCORP?
NCORP is designed to make cancer research findings more generalizable and easier to disseminate by enrolling participants across a wide range of real-world community settings. It aims to bring rigorous clinical trials and other human subjects studies closer to where many patients receive care and to improve how prevention, screening, cancer control, and care delivery evidence is generated and implemented.
What is the core role of an NCORP Research Base?
Research Bases are expected to design, develop, and run multi-institutional cancer control, prevention, and care delivery (CCP and CD) studies. They function as the scientific and operational backbone for studies conducted across multiple participating sites.
What types of studies are Research Bases expected to lead?
Research Bases are expected to lead multi-institutional cancer control, prevention, and care delivery studies, including quality-of-life studies that can be embedded within treatment or imaging trials.
What does it mean that Research Bases are the "research hub" of NCORP?
It means the Research Base is responsible for key centralized research functions, such as developing study concepts, designing protocols, providing statistical leadership, and creating analysis plans that support research implemented across many geographically distributed participating sites.
What scientific leadership functions are expected from a Research Base?
Based on the NOFO description, Research Bases are expected to provide study concept development, protocol design, statistical leadership, and analysis planning for multi-site human subjects research.
What operational responsibilities are expected from a Research Base?
Research Bases are expected to assume responsibility for the full set of study operations and data management functions needed to run complex, multi-site human subjects research. This includes efficient protocol development processes, regulatory compliance, participant protection requirements, and ongoing support for network sites.
What kinds of compliance and oversight expectations apply to Research Bases?
The NOFO highlights regulatory compliance and participant protection requirements aligned with federal expectations and oversight bodies such as the Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP).
Are training, auditing, and quality assurance part of the Research Base expectations?
Yes. The NOFO describes expectations related to auditing, training, quality assurance, and providing ongoing support to the community-facing parts of the network (Community Sites and Academic Community Sites).
Is the Research Base expected to support external participating sites?
Yes. The Research Base is expected to provide ongoing support to Community Sites and Academic Community Sites so that geographically distributed sites can participate consistently, safely, and in compliance with applicable regulations.
How does NCORP relate to the National Clinical Trials Network (NCTN)?
NCORP is positioned to enhance patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN). The NOFO notes that Research Bases may operate in an ecosystem where cancer control and care delivery studies intersect with, or are embedded within, treatment and imaging trials run through NCTN structures.
What kinds of institutions are expected to serve as NCORP Research Bases?
The NOFO indicates Research Bases should be located at institutions with substantial cancer clinical research expertise and established capabilities. Examples include NCI-designated Cancer Centers, healthcare research organizations, NCTN Group Operations Centers, or cancer foundations associated with an NCTN Group.
Why does the NOFO emphasize institutional capability and infrastructure?
The intent is to ensure the awardee has the scientific leadership depth, biostatistical and data management capacity, regulatory infrastructure, and operational experience needed to coordinate many external sites and manage high-quality multi-institutional research.
What types of organizations are eligible to apply?
Eligibility is broad across many U.S.-based organization types, including various levels of government, public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, tribal governments and tribal organizations, and certain housing authorities.
Are non-U.S. (foreign) organizations eligible to apply?
No. Non-U.S. (non-domestic) organizations are not eligible to apply for this opportunity.
Can a U.S. organization apply if the work will be performed by a non-U.S. component of that organization?
No. The NOFO states that non-U.S. components of U.S. organizations are also not eligible to apply.
Are any foreign collaborations allowed under this NOFO?
Yes, "foreign components" (as defined in the NIH Grants Policy Statement) are allowed. This generally means discrete parts of the project may involve foreign collaboration under NIH rules, while the applicant organization and eligible components must remain domestic per the NOFO.
What is the activity category for this opportunity?
The activity category is Health.
What are the Assistance Listing (CFDA) numbers associated with this opportunity?
The Assistance Listing numbers are 93.393 and 93.399.
What type of funding instrument is used?
The funding instrument is a cooperative agreement (UG1).
Is this a discretionary grant opportunity?
Yes. The opportunity is described as discretionary.
How many awards does NCI anticipate making under this NOFO?
The anticipated number of awards is 7.
What is the application closing date listed in the provided information?
The original closing date listed is 2026-09-18.
Is there an award ceiling specified in the provided information?
No award ceiling is specified in the provided source text.
Browse more opportunities from the same category: Health
Next opportunity: Research Facilities Act Program
Previous opportunity: BJA FY25 Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) Investigations Training and Technical Assistance (TTA)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 27 006
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 27 006) also looked into and applied for these:
| Funding Opportunity |
|---|
| Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional) Apply for PAR 27 026 Funding Number: PAR 27 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed) Apply for RFA CA 27 008 Funding Number: RFA CA 27 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing the Scientific Value of Data Generated by the Environmental influences on Child Health Outcomes (ECHO) Program: Dissertation Grant (R36 - Clinical Trial Not Allowed) Apply for RFA OD 27 006 Funding Number: RFA OD 27 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) Apply for RFA OD 27 008 Funding Number: RFA OD 27 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required) Apply for RFA MH 27 140 Funding Number: RFA MH 27 140 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) Apply for RFA NS 27 007 Funding Number: RFA NS 27 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single Source: Cardiothoracic Surgical Trials Network (CTSN) Data Coordinating Center (U01 Clinical Trial Required) Apply for RFA HL 27 002 Funding Number: RFA HL 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Advancing Research on Empirically-Supported Interventions for Older Adults Living with Serious Mental Illness (SMI) (R01 Clinical Trial Optional) Apply for RFA MH 27 180 Funding Number: RFA MH 27 180 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed) Apply for RFA RM 27 014 Funding Number: RFA RM 27 014 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed) Apply for RFA RM 27 015 Funding Number: RFA RM 27 015 Agency: National Institutes of Health Category: Health Funding Amount: $575,000 |
| PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional) Apply for RFA RM 27 012 Funding Number: RFA RM 27 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) Apply for RFA HG 27 011 Funding Number: RFA HG 27 011 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| Limited Competition for the Adolescent Brain Cognitive Development -Extended (ABCD-E) Study Renewal - Data Analysis, Informatics and Resource Center, and Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA DA 27 003 Funding Number: RFA DA 27 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| GREGoRi Technology Integration Center (U01, Clinical Trials Optional) Apply for RFA HG 27 012 Funding Number: RFA HG 27 012 Agency: National Institutes of Health Category: Health Funding Amount: $2,250,000 |
| GREGoRi Innovation Projects (U01 Clinical Trial Optional) Apply for RFA HG 27 013 Funding Number: RFA HG 27 013 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Renewal of the Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AG 27 007 Funding Number: RFA AG 27 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional) Apply for RFA ES 27 004 Funding Number: RFA ES 27 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) Apply for PAR 27 098 Funding Number: PAR 27 098 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) Apply for PA 27 100 Funding Number: PA 27 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional) Apply for RFA RM 27 013 Funding Number: RFA RM 27 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 27 006", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.